Bullfrog AI Holdings, Inc. Overview
Pro stress-test →Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company focused on AI/ML-driven analysis of data sets in medicine and healthcare. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies.
Strategic Profile
Pro stress-test →Bullfrog AI delivers AI solutions including its bfLEAP® platform (originally developed at Johns Hopkins Applied Physics Lab) that analyzes complex biomedical data to uncover patterns, paired with bfPREP™ for data standardization. The company has a collaboration with Sygnature Discovery expected to generate $15–$30 million revenue through 2028.
Competitive Landscape
Pro stress-test →BullFrog AI is positioned with cutting-edge AI technology, exclusive data access, and a capital-efficient operating model within the broader shift toward AI-powered drug development. The company competes against larger pharma analytics platforms and specialized AI drug discovery firms, but maintains differentiation through proprietary brain data access and Johns Hopkins-derived technology.
Industry Context
Bullfrog AI Holdings, Inc. operates in Digital Biopharmaceuticals / AI-Enabled Drug Discovery.
Key facts
Founded: 2017 · Headquarters: Gaithersburg, Maryland · Employees: 9 · Market cap: $6.7M